Literature DB >> 1712272

Enalaprilat, but not cilazaprilat, increases inflammatory skin reactions in guinea-pigs.

R G Andersson1, B E Karlberg, B R Lindgren, K Persson, U Rosenqvist.   

Abstract

The inflammatory effects of enalaprilat and cilazaprilat were tested in an experimental model of ovalbumin-sensitised guinea-pigs. Enalaprilat, but not cilazaprilat, enhanced the ovalbumin-induced inflammatory skin responses. The effect of enalaprilat was dose-dependent. Enalaprilat significantly increased the skin content of substance P and histamine. Cilazaprilat did not alter the level of these inflammatory mediators. Enalaprilat, applied locally, but not cilazaprilat, enhanced the inflammatory reactions caused by intradermal injections of allergen and substance P. Both angiotensin converting enzyme (ACE) inhibitors enhanced the inflammatory skin response evoked by bradykinin. Our study strongly indicates that enalaprilat has pro-inflammatory properties, whereas the new long-acting ACE inhibitor cilazaprilat does not. This might give a better safety profile of cilazaprilat.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1712272     DOI: 10.2165/00003495-199100411-00009

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  22 in total

1.  A BRADYKININ-POTENTIATING FACTOR (BPF) PRESENT IN THE VENOM OF BOTHROPS JARARCA.

Authors:  S H FERREIRA
Journal:  Br J Pharmacol Chemother       Date:  1965-02

2.  The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1988-05

3.  1989 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting.

Authors: 
Journal:  J Hypertens       Date:  1989-08       Impact factor: 4.844

4.  Angiotensin converting enzyme inhibitors and cough.

Authors:  G I Town; G P Hallwright; T J Maling; T V O'Donnell
Journal:  N Z Med J       Date:  1987-03-25

Review 5.  Clinical applications of angiotensin-converting enzyme inhibitors.

Authors:  R K Ferguson; P H Vlasses; H H Rotmensch
Journal:  Am J Med       Date:  1984-10       Impact factor: 4.965

6.  Potentiation of inflammatory reactions in guinea-pig skin by an angiotensin converting enzyme inhibitor (MK 422).

Authors:  B R Lindgren; C D Anderson; R G Andersson
Journal:  Eur J Pharmacol       Date:  1987-03-31       Impact factor: 4.432

7.  Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.

Authors:  M A Ondetti; B Rubin; D W Cushman
Journal:  Science       Date:  1977-04-22       Impact factor: 47.728

8.  Asthma and increases in nonallergic bronchial responsiveness from seasonal pollen exposure.

Authors:  L P Boulet; A Cartier; N C Thomson; R S Roberts; J Dolovich; F E Hargreave
Journal:  J Allergy Clin Immunol       Date:  1983-04       Impact factor: 10.793

9.  Carboxyl-terminal tripeptidyl hydrolysis of substance P by purified rabbit lung angiotensin-converting enzyme and the potentiation of substance P activity in vivo by captopril and MK-422.

Authors:  M A Cascieri; H G Bull; R A Mumford; A A Patchett; N A Thornberry; T Liang
Journal:  Mol Pharmacol       Date:  1984-03       Impact factor: 4.436

10.  A specific orally active inhibitor of angiotensin-converting enzyme in man.

Authors:  R K Ferguson; G A Turini; H R Brunner; H Gavras; D N McKinstry
Journal:  Lancet       Date:  1977-04-09       Impact factor: 79.321

View more
  1 in total

Review 1.  ACE inhibitor-induced angioedema. Incidence, prevention and management.

Authors:  W Vleeming; J G van Amsterdam; B H Stricker; D J de Wildt
Journal:  Drug Saf       Date:  1998-03       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.